Dextran-coated iron oxide nanoparticle for delivery of miR-29a to breast cancer cell line

被引:17
作者
Yalcin, Serap [1 ]
机构
[1] Kirsehir Ahi Evran Univ, Dept Mol Biol & Genet, TR-40100 Kirsehir, Turkey
关键词
MiR-29a; nanoparticles; breast cancer; dextran; apoptosis; IN-VIVO DELIVERY; TARGETED DELIVERY; MICRORNA THERAPEUTICS; THERAPY; GROWTH; NANOMEDICINE; DOXORUBICIN; STATISTICS; EXPRESSION; DIAGNOSIS;
D O I
10.1080/10837450.2019.1623252
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the last years, miRNAs have been associated with molecular pathways of cancer and other diseases. The change of expression level of miRNA has an inhibitory role in tumorigenesis. Nevertheless, the poor bioavailability of miRNA due to the rapid enzymatic degradation is a critical handicap in cancer therapy. In this study, we designed dextran-coated iron oxide-based nanoparticle for the delivery of miR-29a to breast cancer cells and analyzed its therapeutic efficacy in vitro. Results indicated that the presence of dextran-coated magnetic nanoparticles, loaded with miR29a, enhanced the selective delivery of miR-29a. Further, miR-29a complex nanoparticles caused down-regulation of anti-apoptotic genes. These results pave the way for further investigations into the possible use of miR-29a complex magnetic nanoparticles for breast cancer therapy.
引用
收藏
页码:1032 / 1037
页数:6
相关论文
共 43 条
[21]   Doxorubicin in sterically stabilized liposomes [J].
Lasic, DD .
NATURE, 1996, 380 (6574) :561-562
[22]   THE P53 TUMOR SUPPRESSOR GENE [J].
LEVINE, AJ ;
MOMAND, J ;
FINLAY, CA .
NATURE, 1991, 351 (6326) :453-456
[23]   RETRACTED: miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker (Retracted article. See vol. 18, pg. 2017, 2023) [J].
Li, Feng ;
Wang, Feiran ;
Zhu, Changlai ;
Wei, Qun ;
Zhang, Tianyi ;
Zhou, You Lang .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2018, 13 :2295-2307
[24]   miR-29a regulated ER-positive breast cancer cell growth and invasion and is involved in the insulin signaling pathway [J].
Li, Zhi-hua ;
Xiong, Qiu-yun ;
Xu, Liang ;
Duan, Peng ;
Yang, Qianwen Ou ;
Zhou, Ping ;
Tu, Jian-Hong .
ONCOTARGET, 2017, 8 (20) :32566-32575
[25]   Therapeutic targeting of microRNAs: current status and future challenges [J].
Li, Zhonghan ;
Rana, Tariq M. .
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (08) :622-638
[26]   Engineering Nanocomposite Materials for Cancer Therapy [J].
Minelli, Caterina ;
Lowe, Stuart B. ;
Stevens, Molly M. .
SMALL, 2010, 6 (21) :2336-2357
[27]   Nanomedicine: current status and future prospects [J].
Moghimi, SM ;
Hunter, AC ;
Murray, JC .
FASEB JOURNAL, 2005, 19 (03) :311-330
[28]   MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines [J].
Muniyappa, M. K. ;
Dowling, P. ;
Henry, M. ;
Meleady, P. ;
Doolan, P. ;
Gammell, P. ;
Clynes, M. ;
Barron, N. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (17) :3104-3118
[29]   Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer [J].
Perepelyuk, Maryna ;
Sacko, Koita ;
Thangavel, Karthik ;
Shoyele, Sunday A. .
MOLECULAR PHARMACEUTICS, 2018, 15 (03) :985-993
[30]   Circulating microRNAs: Association with disease and potential use as biomarkers [J].
Reid, Glen ;
Kirschner, Michaela B. ;
van Zandwijk, Nico .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 80 (02) :193-208